Literature DB >> 16807273

Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

A L Baggish1, R N Smith, I Palacios, G J Vlahakes, D M Yoerger, M H Picard, P A Lowry, I-K Jang, M A Fifer.   

Abstract

BACKGROUND: The pathological effects and the mechanisms of action of intracoronary administration of ethanol for alcohol septal ablation (ASA) for the management of hypertrophic obstructive cardiomyopathy (HOCM) are unknown.
METHODS: We examined surgical specimens and, in one case, autopsy specimens from four patients who underwent surgical septal myectomy 2 days to 14 months after unsuccessful ASA.
RESULTS: Pathological examination early after ASA showed coagulative necrosis of both the myocardium and the septal perforator arteries. Affected arteries were distended and occluded by necrotic intraluminal debris, without platelet-fibrin thrombi. Late after unsuccessful ASA, excised septal tissue was heterogeneous, containing a region of dense scar, and adjacent tissue containing viable myocytes and interspersed scar.
CONCLUSIONS: Intracoronary administration of ethanol in patients with HOCM causes acute myocardial infarction with vascular necrosis. The coagulative necrosis of the arteries, their distension by necrotic debris and the absence of platelet-fibrin thrombi distinguish ethanol-induced infarction from that caused by atherosclerotic coronary artery disease. The direct vascular toxicity of ethanol may be an important aspect of the mechanism of successful ASA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807273      PMCID: PMC1861291          DOI: 10.1136/hrt.2006.092007

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Anteroapical stunning and left ventricular outflow tract obstruction.

Authors:  R P Villareal; A Achari; S Wilansky; J M Wilson
Journal:  Mayo Clin Proc       Date:  2001-01       Impact factor: 7.616

2.  Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up.

Authors:  N M Lakkis; S F Nagueh; J K Dunn; D Killip; W H Spencer
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

3.  Images in cardiovascular medicine. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy: initial success but ultimate failure resulting from collateral formation.

Authors:  Michael A Fifer; Danita M Yoerger; Michael H Picard; Gus J Vlahakes; Igor F Palacios
Journal:  Circulation       Date:  2003-07-01       Impact factor: 29.690

4.  Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction.

Authors:  P o Hui Chiang; Yao Chi Chuang; Chao Cheng Huang; Chin Pei Chiang
Journal:  Urology       Date:  2003-04       Impact factor: 2.649

5.  Myectomy for hypertrophic obstructive cardiomyopathy after failed alcohol septal ablation: clinicopathological correlations.

Authors:  A A Arrazaghi; J W Butany; W G Williams ; D E Wigle ; H Rakowski
Journal:  Can J Cardiol       Date:  2001-02       Impact factor: 5.223

6.  Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan.

Authors:  K Tsuchihashi; K Ueshima; T Uchida; N Oh-mura; K Kimura; M Owa; M Yoshiyama; S Miyazaki; K Haze; H Ogawa; T Honda; M Hase; R Kai; I Morii
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

7.  Advanced management of venous malformation with ethanol sclerotherapy: mid-term results.

Authors:  B B Lee; Y S Do; H S Byun; I W Choo; D I Kim; S H Huh
Journal:  J Vasc Surg       Date:  2003-03       Impact factor: 4.268

8.  The role of transarterial embolization in the treatment of renal cell carcinoma.

Authors:  N P Munro; S Woodhams; J D Nawrocki; M S Fletcher; P J Thomas
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

9.  Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study.

Authors:  T I Huo; Y H Huang; J C Wu; P C Lee; F Y Chang; S D Lee
Journal:  Scand J Gastroenterol       Date:  2003-07       Impact factor: 2.423

10.  Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy.

Authors:  Ute Raute-Kreinsen
Journal:  Pathol Res Pract       Date:  2003       Impact factor: 3.250

View more
  13 in total

1.  Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Silke Daci; Barbara Pfeiffer; Konstadia Papadopoulou; Anna Neugebauer; Hubert Seggewiss
Journal:  Clin Res Cardiol       Date:  2016-06-06       Impact factor: 5.460

2.  Transcatheter Myocardial Needle Chemoablation During Real-Time Magnetic Resonance Imaging: A New Approach to Ablation Therapy for Rhythm Disorders.

Authors:  Toby Rogers; Srijoy Mahapatra; Steven Kim; Michael A Eckhaus; William H Schenke; Jonathan R Mazal; Adrienne Campbell-Washburn; Merdim Sonmez; Anthony Z Faranesh; Kanishka Ratnayaka; Robert J Lederman
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-04

Review 3.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

4.  Septal myectomy after failed septal alcohol ablation.

Authors:  Eduard Quintana; Pietro Bajona; María José Arguis; Susanna Prat-González
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy.

Authors:  Xiaofang Lu; Douglas L Miller; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2016-04-14       Impact factor: 2.998

6.  Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Rachael Fuller; Kristina Fields; Mario L Fabiilli; Gabe E Owens; David Gordon; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2018-04-19       Impact factor: 2.998

7.  A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Authors:  Terri A Addona; Xu Shi; Hasmik Keshishian; D R Mani; Michael Burgess; Michael A Gillette; Karl R Clauser; Dongxiao Shen; Gregory D Lewis; Laurie A Farrell; Michael A Fifer; Marc S Sabatine; Robert E Gerszten; Steven A Carr
Journal:  Nat Biotechnol       Date:  2011-06-19       Impact factor: 54.908

8.  Microvascular permeability changes might explain cardiac tamponade after alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  Jen-Te Hsu; Ju-Feng Hsiao; Jung-Jung Chang; Chang-Min Chung; Shih-Tai Chang; Kuo-Li Pan
Journal:  Tex Heart Inst J       Date:  2014-04-01

9.  Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.

Authors:  Gregory D Lewis; Ru Wei; Emerson Liu; Elaine Yang; Xu Shi; Maryann Martinovic; Laurie Farrell; Aarti Asnani; Marcoli Cyrille; Arvind Ramanathan; Oded Shaham; Gabriel Berriz; Patricia A Lowry; Igor F Palacios; Murat Taşan; Frederick P Roth; Jiangyong Min; Christian Baumgartner; Hasmik Keshishian; Terri Addona; Vamsi K Mootha; Anthony Rosenzweig; Steven A Carr; Michael A Fifer; Marc S Sabatine; Robert E Gerszten
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.